We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urinary Detection Method Developed for Prostate Cancer

By LabMedica International staff writers
Posted on 22 Jan 2019
Prostate cancer (PCa) is one of the most common types of malignancy worldwide and is the second leading cause of cancer death among men. More...
This cancer tends to be asymptomatic and slow growing, often with onset in young men, but usually not detected until the age of 40 to 50 years.

The conventional methods for PCa screening recommended by the American Cancer Society are serum prostate specific antigen (PSA) testing and digital rectal examination (DRE). However, these methods have some drawbacks due to their sensitivity, specificity and accuracy. The PCA3 gene has shown promise as a non-invasive PCa biomarker.

Scientists at Mahidol University (Bangkok, Thailand) collected spot urine samples from five healthy male volunteers, first voided post-DRE urine from five benign prostate hyperplasia (BPH) patients and from five PCa patients. Diagnosis of patients was made by histopathological analysis after prostate biopsy subsequently. PCa patients were identified with positive biopsy.

Total RNA was isolated from the cell pellets of urine as well as from cell lines and total RNA was converted to cDNA using RevertAid First Strand cDNA synthesis kit. The team developed an assay based on interactions between unmodified gold nanoparticles (AuNPs) and thiolated polymerase chain reaction (PCR) products. Thiolated PCR products were amplified by RT-PCR using a thiol-labeled primer at the 5′ end. Thiolated products of PCA3 bound to the surface of AuNPs and led to the prevention of salt-induced aggregation (red color). In the absence of the PCR products, AuNPs changed their color from red to blue due to the salt-induced aggregation. These changes were detected by the naked eye and a microplate spectrophotometer.

The team reported that assay was specific for PCA3 in prostate cancer cell lines with a visual detection limit of 31.25 ng/reaction. The absorption ratio 520/640 nm was linear against PCR product concentration in the reaction. This method is promising for discrimination of prostate cancer patients from both healthy controls and benign prostatic hyperplasia patients according to their urinary PCA3 expression levels. The results indicated that the proposed colorimetric assay was more sensitive than gel electrophoresis.

The authors concluded that a sensitive and specific AuNP-based colorimetric method for visual detection of PCA3 in prostate cancer was successfully developed. This new method was based on interactions between thiolated PCR products and unmodified AuNPs. The positive and negative results were clearly distinguished by the naked eye, being red and blue color, respectively. The incubation time was short and results were obtained within 10 minutes of RT-PCR completion. Moreover, a large number of samples could be tested simultaneously in 96-well microtiter plates. The study was published in the January 2019 issue of the journal Clinica Chimica Acta.

Related Links:
Mahidol University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Guardant Health has introduced new applications for Guardant360 Liquid, expanding the test’s capabilities for treatment selection in breast and lung cancers. (Photo courtesy of Guardant Health)

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.